Efficiency and Risk Factors for CMV Transmission in Seronegative Hematopoietic Stem Cell Recipients

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 9, 2012, Pages 1391-1400

  Pergam, Steven A ^a,b   Xie, Hu ^a   Sandhu, Ravinder ^a   Pollack, Margaret ^a,b   Smith, Jeremy ^c   Stevens Ayers, Terry ^a   Ilieva, Valeria ^a   Kimball, Louise E ^a   Huang, Meei Li ^b   Hayes, Tracy S ^b   Corey, Lawrence ^a,b   Boeckh, Michael J ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

Author keywords

Cytomegalovirus; Donor; Graft; Transmission

Indexed keywords

ACICLOVIR; ANTIINFECTIVE AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; VALACICLOVIR; VIRUS DNA;

ADULT; ARTICLE; BACTEREMIA; CANDIDEMIA; CELL COUNT; COHORT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FEMALE; GASTROINTESTINAL DISEASE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAM NEGATIVE INFECTION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; HUMAN TISSUE; INFECTION RISK; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PERIPHERAL BLOOD STEM CELL; PNEUMOCYSTOSIS; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCREENING; SYSTEMIC MYCOSIS; VIRUS DETECTION; VIRUS GENOME; VIRUS PNEUMONIA; VIRUS SHEDDING; VIRUS TRANSMISSION; WHOLE BODY RADIATION;

ADULT; ANTIBODIES, VIRAL; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 84865175106     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.02.008     Document Type: Article

References (52)

1. Boeckh M., Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004, 103:2003-2008.
2. Nichols W.G., Corey L., Gooley T., Davis C., Boeckh M. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis 2002, 185:273-282.
3. George B., Pati N., Gilroy N., et al. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy. Transpl Infect Dis 2010, 12:322-329.
4. Walker C.M., van Burik J.A., De For T.E., Weisdorf D.J. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biol Blood Marrow Transplant 2007, 13:1106-1115.
5. Matthes-Martin S., Lion T., Aberle S.W., et al. Pre-emptive treatment of CMV DNAemia in paediatric stem cell transplantation: the impact of recipient and donor CMV serostatus on the incidence of CMV disease and CMV-related mortality. Bone Marrow Transplant 2003, 31:803-808.
6. Trenschel R., Ross S., Husing J., et al. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT. Bone Marrow Transplant 2000, 25:665-672.
7. Bowden R.A., Slichter S.J., Sayers M., et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995, 86:3598-3603.
8. Nichols W.G., Price T.H., Gooley T., Corey L., Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood 2003, 101:4195-4200.
9. Boeckh M., Fries B., Nichols W.G. Recent advances in the prevention of CMV infection and disease after hematopoietic stem cell transplantation. Pediatr Transplant 2004, 8(Suppl 5):19-27.
10. Mocarski E.S., Shenk T., Pass R. Cytomegaloviruses. Field's Virology 2007, 2701-2772. Lippincott Williams & Wilkins, Philadelphia, PA. D. Knipe, P. Howley, D. Griffin (Eds.).
11. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
12. Boeckh M., Huang M., Ferrenberg J., et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol 2004, 42:1142-1148.
13. Boeckh M., Gallez-Hawkins G.M., Myerson D., Zaia J.A., Bowden R.A. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997, 64:108-113.
14. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996, 88:4063-4071.
15. Nakamae H., Kirby K.A., Sandmaier B.M., et al. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2009, 15:694-703.
16. Erard V., Guthrie K.A., Varley C., et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 2007, 110:3071-3077.
17. de Gast G.C., Boland G.J., Vlieger A.M., et al. Abortive human cytomegalovirus infection in patients after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992, 9:221-225.
18. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
19. De Pauw B., Walsh T.J., Donnelly J.P., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
20. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
21. Junghanss C., Boeckh M., Carter R.A., et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood 2002, 99:1978-1985.
22. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
23. Ljungman P., Brand R., Einsele H., Frassoni F., Niederwieser D., Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003, 102:4255-4260.
24. Kollman C., Howe C.W., Anasetti C., et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001, 98:2043-2051.
25. Meyers J.D., Flournoy N., Thomas E.D. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986, 153:478-488.
26. Boeckh M., Ljungman P. Cytomegalovirus infection after hemopoietic stem cell transplantation. Transplant Infections 2003, 277-297. Lippincott Williams & Wilkins, Philadelphia, PA. R.A. Bowden, P. Ljungman, C. Paya (Eds.).
27. Slobedman B., Mocarski E.S. Quantitative analysis of latent human cytomegalovirus. J Virol 1999, 73:4806-4812.
28. Kondo K., Xu J., Mocarski E.S. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc Natl Acad Sci USA 1996, 93:11137-11142.
29. Kondo K., Kaneshima H., Mocarski E.S. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc Natl Acad Sci USA 1994, 91:11879-11883.
30. Kondo K., Mocarski E.S. Cytomegalovirus latency and latency-specific transcription in hematopoietic progenitors. Scand J Infect Dis Suppl 1995, 99:63-67.
31. Hahn G., Jores R., Mocarski E.S. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc Natl Acad Sci USA 1998, 95:3937-3942.
32. Taylor-Wiedeman J., Sissons J.G., Borysiewicz L.K., Sinclair J.H. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J Gen Virol 1991, 72(Pt 9):2059-2064.
33. Stanier P., Taylor D.L., Kitchen A.D., Wales N., Tryhorn Y., Tyms A.S. Persistence of cytomegalovirus in mononuclear cells in peripheral blood from blood donors. BMJ 1989, 299:897-898.
34. Champlin R.E., Schmitz N., Horowitz M.M., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000, 95:3702-3709.
35. Soderberg-Naucler C., Fish K.N., Nelson J.A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997, 91:119-126.
36. Manteiga R., Martino R., Sureda A., et al. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience. Bone Marrow Transplant 1998, 22:899-904.
37. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001, 344:175-181.
38. Korbling M., Huh Y.O., Durett A., et al. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 1995, 86:2842-2848.
39. Ottinger H.D., Beelen D.W., Scheulen B., Schaefer U.W., Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996, 88:2775-2779.
40. Junghanss C., Storb R., Maris M.B., et al. Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non-myeloablative allogeneic stem cell transplantation. Br J Haematol 2003, 123:662-670.
41. Martino R., Caballero M.D., Canals C., et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001, 28:341-347.
42. Ljungman P., Aschan J., Lewensohn-Fuchs I., et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 1998, 66:1330-1334.
43. Miller W., Flynn P., McCullough J., et al. Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease. Blood 1986, 67:1162-1167.
44. Hutson A.M., Atmar R.L., Graham D.Y., Estes M.K. Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis 2002, 185:1335-1337.
45. Hudnall S.D., Chen T., Rady P., Tyring S., Allison P. Human herpesvirus 8 seroprevalence and viral load in healthy adult blood donors. Transfusion 2003, 43:85-90.
46. Garratty G., Glynn S.A., McEntire R. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion 2004, 44:703-706.
47. Buyck H.C., Prentice H.G., Griffiths P.D., Emery V.C. The risk of early and late CMV DNAemia associated with Campath use in stem cell transplant recipients. Bone Marrow Transplant 2010, 45:1212-1219.
48. Correia-Silva Jde F., Victoria J.M., Guimaraes A.L., et al. Cytomegalovirus shedding in the oral cavity of allogeneic haematopoietic stem cell transplant patients. Oral Dis 2007, 13:163-169.
49. Preiser W., Brauninger S., Schwerdtfeger R., et al. Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants. J Clin Virol 2001, 20:59-70.
50. Sola R., Rabella N., Guirado L.L., Diaz J.M., Facundo C., Garcia R. Relation between pp65 antigenemia, RT-PCR and viruria for cytomegalovirus detection in kidney transplant recipients. Transplant Proc 2005, 37:3768-3769.
51. Bowden R.A., Fisher L.D., Rogers K., Cays M., Meyers J.D. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 1991, 164:483-487.
52. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363:2091-2101.